Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 581

Sort by

Sort Order Select

Journal Articles

Antibiotics: bad bugs for CAR-T cells?

Florent Malard, Mohamad Mohty

Blood (2025) 145 (8): 787–788.

https://doi.org/10.1182/blood.2024027102

Published: 2025

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Dr, Martine Escoffre-Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean Marc Schiano de Colella, Mourad Tiab, Mohamad Mohty, Frédérique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hébraud, Laurent Flet, Jean-Valère Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cécile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Hélène Demarquette, Valentine Richez, Cherel Bruiec, Laurent Frenzel, Marie-Christiane MB Vekemans, Noemie Bigot, Hervé Avet-Loiseau, Jill Corre, Philippe Moreau

Blood blood.2024026230.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte

Blood (2024) 144 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2024-203723

Published: 2024

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Blood (2024) 144 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2024-200501

Published: 2024

Journal Articles

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2024-206733

Published: 2024

Journal Articles

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2024-200423

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT

Eolia Brissot, Myriam Labopin, Didier Blaise, Cristina Castilla-Llorente, Annoek E. C. Broers, Nicolaus Kröger, Jakob R. Passweg, Andrew Bruce McDonald, Lucía López-Corral, Zinaida Peric, Sebastian Giebel, Arnon Nagler, Mohamad Mohty, Fabio Ciceri, Francesca Kinsella, Ludovic Gabellier

Blood (2024) 144 (Supplement 1): 508.

https://doi.org/10.1182/blood-2024-207681

Published: 2024

Journal Articles

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Blood (2024) 144 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2024-202764

Published: 2024

Journal Articles

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2024-208242

Published: 2024

Journal Articles

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Blood (2024) 144 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2024-206867

Published: 2024

Journal Articles

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 693.

https://doi.org/10.1182/blood-2024-203472

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP

Jan Vydra, Allain-Thibeault Ferhat, Nicolaus Kröger, Tobias Gedde-Dahl, Matthias Eder, Thomas Schroeder, Urpu Salmenniemi, Gerard Socie, Jakob Passweg, Sr., Ibrahim Yakoub-Agha, Alessandro Rambaldi, Robert Zeiser, Matthias Stelljes, Kristina Carlson, Cristina Castilla-Llorente, Alexandros Spyridonidis, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2024-198999

Published: 2024

Journal Articles

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2024-200458

Published: 2024

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Nicolaus Kröger, Matthias Eder, Gerard Socie, Didier Blaise, Thomas Schroeder, Hélène Labussière-Wallet, Johan Maertens, Alessandro Busca, Edouard Forcade, Tobias Gedde-Dahl, Alessandro Rambaldi, Claude-Éric Bulabois, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 505.

https://doi.org/10.1182/blood-2024-194057

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT

Frederic Baron, Allain Thibeault Ferhat Berland, Myriam Labopin, Matthias Eder, Alessandro Rambaldi, Cristina Castilla-Llorente, Igor Wolfgang Blau, Francesca Bonifazi, Thomas Schroeder, Nicolaus Kröger, Didier Blaise, Peter Dreger, Tobias Gedde-Dahl, Jaime Sanz, Mohamad Mohty, Fabio Ciceri

Blood (2024) 144 (Supplement 1): 4895.

https://doi.org/10.1182/blood-2024-199632

Published: 2024

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

NARROW

Antibiotics: bad bugs for CAR-T cells?

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only